AstraZeneca's Capivasertib and Fulvestrant Combo Offers Hope for Advanced Breast Cancer
The CAPItello-291 trial by AstraZeneca reveals promising results with capivasertib and fulvestrant for advanced HR+/HER2− breast cancer patients. Significant enhancement in progression-free survival and maintained quality of life suggest a new potential treatment pathway.
